A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage

Journal of Intensive Care Medicine - Tập 30 Số 8 - Trang 462-472 - 2015
Rohit Kumar1, Roy E. Smith1, Brian L. Henry2
1Division of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
2Department of Cardiology and the Vascular Medicine Institute, University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, PA, USA

Tóm tắt

Dabigatran is an oral direct thrombin inhibitor that is approved for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Dabigatran has several advantages over warfarin including predictable pharmacokinetics and pharmacodynamics which eliminates the need for routine laboratory monitoring, superiority over warfarin in preventing stroke, or systemic embolism without having an increased risk of bleeding. However, as with any anticoagulant, there remains a real chance of bleeding, including major or life-threatening hemorrhage. Many physicians feel comfortable managing bleeding complications on older anticoagulants like warfarin and heparin, due to extensive experience with the medications along with antidotes to reverse their effects as well as established protocols for treating anticoagulant-associated hemorrhage. However, most physicians have limited clinical experience with dabigatran, there is no specific antidote for dabigatran reversal and there is a paucity of protocols, guidelines, and recommendations for how to manage dabigatran-associated hemorrhage. In this review, we present a case series of patients admitted to our institution for management of bleeding while receiving dabigatran. We retrospectively reviewed these cases to evaluate the efficacy and rationale of the various anticoagulation reversal strategies employed in the context of the existing evidence found in the literature. Specific focus is placed on the therapies utilized and the coagulation studies used to manage these patients.

Từ khóa


Tài liệu tham khảo

10.1177/1076029609343004

van Ryn J, 2008, Arterioscler Thromb Vasc Biol, 28, e136

10.1161/CIRCULATIONAHA.110.004424

10.1111/j.1365-2125.2007.02899.x

10.1056/NEJMoa0905561

10.1160/TH09-11-0758

10.1002/clc.22037

10.1093/eurheartj/ehr113

10.1161/CIRCULATIONAHA.112.115386

10.1053/j.seminhematol.2010.04.001

10.2165/11318170-000000000-00000

10.1160/TH11-11-0804

10.1345/aph.1R720

10.2215/CJN.01570213

10.1016/j.amjmed.2011.10.017

10.2165/00003088-200847010-00005

10.1309/AJCPY6G6ZITVKPVH

10.1159/000081506

10.1007/s11239-013-0907-y

10.1007/s00228-013-1550-4

10.1378/chest.11-2292

van Ryn J, 2009, 51st ASH Annual Meeting and Exposition

10.1002/ajh.23202

10.1053/j.ajkd.2012.08.047

10.1182/blood-2011-11-393587

10.1160/TH12-08-0573

10.4065/79.12.1495

10.1016/j.jclinane.2007.12.012

10.1160/TH12-03-0179

van Ryn J, 2008, Haematologica, 93, 148

10.1056/NEJMoa1006221

10.1016/S0140-6736(07)61199-4

10.1161/STROKEAHA.111.624650

10.1161/CIRCULATIONAHA.111.029017

10.1161/CIRCULATIONAHA.112.123224

10.1097/CCM.0b013e31827caaa3

10.1160/TH11-01-0052

Friedman KD, 2001, Williams’ Hematology, 6th ed, 1917

10.1111/j.1537-2995.2005.00184.x

10.1002/ajh.2830390204

10.1056/NEJM198301063080102

Thông tin
Thông tin xuất bản

Journal of Intensive Care Medicine

Tập 30 Số 8

462-472

Thông tin tác giả